clinical investigators

Clinical Trial Ethics

Industry Insights from Paul Meade, M. Sc, MPH According to an article published in the Archives of Internal Medicine, Dr Joseph Ross claimed a study conducted by Parke-Davis, before it was acquired by Pfizer, using gabapentin (Neurontin), as the drug under investigation, appeared to be a “seeding” trial. And while the author states that seeding …

Clinical Trial Ethics Read More »

Thought Leader Select delivers KOL identification research to five leading pharma companies in the U.S. and Canada

April 15, 2010 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based firm dedicated to delivering solutions for key opinion leader (KOL) management for the biopharmaceutical industry, has announced the delivery of KOL identification projects for five leading North American pharmaceutical companies during the first quarter of 2010. Five of the world’s largest pharmaceutical concerns contracted …

Thought Leader Select delivers KOL identification research to five leading pharma companies in the U.S. and Canada Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective, methodical approach to understanding KOLs’ and clinical investigators’ skills and experiences. Many methods promise to …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs are physicians, scientists and academics who devote time to studying and advancing their craft. Often, …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four Read More »

Industry Contraction Spurs New Partnership Opportunities

According to a February 2010 article in Outsourcing-Pharma.com, pharmaceutical companies will continue to outsource more of their business to single-service providers. To capture more business, CROs will merge or focus on niche opportunities. Thought Leader Select, a research firm providing sophisticated KOL deployment strategies to the pharma and biotech industries, has developed a unique opportunity …

Industry Contraction Spurs New Partnership Opportunities Read More »